{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T05:54:06Z","timestamp":1791525246788,"version":"4.3.4"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T00:00:00Z","timestamp":1701302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013373","name":"NIHR Oxford Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Late presentation of multiple myeloma (MM) heightens the risk of complication risks, including end-organ damage. This study aimed to: 1) detail the diagnostic journey of MM patients, encompassing symptoms, initial diagnoses, and healthcare professionals met; 2) establish the median duration from symptom onset to MM diagnosis; and 3) examine factors linked to timely MM diagnosis within 12 weeks. <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 300 adults self-reporting MM were analysed from the Rare and Undiagnosed Diseases cohort Study (RUDY). The RUDY study is a web-based platform, where participants provide dynamic consent and self-report their MM diagnosis and information about their diagnostic journey. This includes the estimated date of initial potential first symptoms, descriptions of these symptoms, the healthcare professionals they consulted, and other diagnoses received before the MM diagnosis. Descriptive statistics, combinatorial analyses and logistic regression analyses were used to describe and examine the diagnostic journey of individuals with MM.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 52% of the participants reported other diagnoses before MM diagnosis, with musculoskeletal disorders (47.8%), such as osteoporosis, costochondritis, or muscle strains, being the most common. The most prevalent initial reported symptom was back pain\/vertebral fractures (47%), followed by chest\/shoulder pain, including rib pain and fractures (20%), and fatigue\/tiredness (19.7%). 40% of participants were diagnosed by direct referral from primary care to haematology without seeing other healthcare professionals whilst 60% consulted additional specialists before diagnosis. The median time from symptom onset to MM diagnosis was 4 months (IQR 2-10 months, range 0-172). Seeing an Allied Healthcare Professional such as a physiotherapist, chiropractor or an osteopath (OR = 0.25, 95% CI [0.12, 0.47], p &amp;lt;0.001), experiencing infection symptoms (OR = 0.32, 95% CI [0.13, 0.76], p = 0.013), and having chest or shoulder pain (OR = 0.45, 95% CI [0.23, 0.86], p = 0.020) were associated with a lower likelihood of being diagnosed with MM within 12 weeks. Older age (OR = 1.04, 95% CI [1.02, 1.07], p = 0.001) was associated with a higher likelihood of diagnosis within 12 weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Developing resources for allied health professionals may improve early recognition of MM.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2023.1282569","type":"journal-article","created":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T08:32:47Z","timestamp":1701333167000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Patient-reported symptoms and diagnostic journey in Multiple Myeloma"],"prefix":"10.3389","volume":"13","author":[{"given":"Rohit","family":"Vijjhalwar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshi","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Bowcock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria T.","family":"Sanchez-Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik","family":"Ramasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Kassim","family":"Javaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"key":"B2","volume-title":"Cancer Stat Facts: Myeloma","year":""},{"key":"B3","unstructured":"Cancer Research UK Myeloma incidence statistics"},{"key":"B4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"B5","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s12885-020-6596-y","article-title":"Bone complications in patients with multiple myeloma in five European countries: a retrospective patient chart review","volume":"20","author":"Mateos","year":"2020","journal-title":"BMC Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2000.90221.x","article-title":"Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group","volume":"65","author":"Knudsen","year":"2000","journal-title":"Eur J Haematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2005.01.024","article-title":"Neurological aspects of multiple myeloma and related disorders","volume":"18","author":"Dispenzieri","year":"2005","journal-title":"Best Pract Res Clin Haematol"},{"key":"B8","volume-title":"The current STATs of blood cancer diagnosis in England: an end the delays campaign report","year":"2019"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.408","article-title":"Routes to diagnosis for cancer \u2013 determining the patient journey using multiple routine data sets","volume":"107","author":"Elliss-Brookes","year":"2012","journal-title":"Br J Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-052759","article-title":"Clinical features and diagnosis of multiple myeloma: a population-based cohort study in primary care","volume":"11","author":"Seesaghur","year":"2021","journal-title":"BMJ Open"},{"key":"B11","unstructured":"A Life Worth Living2022"},{"key":"B12","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1111\/bjh.17044","article-title":"Diagnostic pathways in multiple myeloma and their relationship to end organ damage: an analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) trial","volume":"192","author":"Atkin","year":"2021","journal-title":"Br J Haematol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1182\/blood-2021-150848","article-title":"An in depth analysis of factors contributing to diagnostic delay in myeloma: A retrospective UK study of patients journey from primary care to specialist secondary care","volume":"138","author":"Hossain","year":"2021","journal-title":"Blood"},{"key":"B14","unstructured":"Routes to diagnosis 2006-20152017"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp17X694169","article-title":"Diagnosing cancer in primary care: results from the National Cancer Diagnosis Audit","volume":"68","author":"Swann","year":"2018","journal-title":"Br J Gen Pract"},{"key":"B16","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1080\/10428190902741471","article-title":"Diagnostic delay and complications for older adults with multiple myeloma","volume":"50","author":"Friese","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"B17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/2052-1839-13-9","article-title":"Time-to-diagnosis and symptoms of myeloma, lymphomas and leukaemias: a report from the Haematological Malignancy Research Network","volume":"13","author":"Howell","year":"2013","journal-title":"BMC Hematol"},{"key":"B18","unstructured":"NHS Cancer Programme: Faster Diagnosis Framework2022"},{"key":"B19","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/bjh.14513","article-title":"Multiple myeloma: routes to diagnosis, clinical characteristics and survival \u2013 findings from a UK population-based study","volume":"177","author":"Howell","year":"2017","journal-title":"Br J Haematol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0194788","article-title":"Myeloma: Patient accounts of their pathways to diagnosis","volume":"13","author":"Howell","year":"2018","journal-title":"PLoS One"},{"key":"B21","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s13023-016-0528-6","article-title":"The RUDY study platform - a novel approach to patient driven research in rare musculoskeletal diseases","volume":"11","author":"Javaid","year":"2016","journal-title":"Orphanet J Rare Dis"},{"key":"B22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/2049-3258-72-35","article-title":"The EPIRARE proposal of a set of indicators and common data elements for the European platform for rare disease registration","volume":"72","author":"Taruscio","year":"2014","journal-title":"Arch Public Health"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17410","article-title":"Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for Haematology\/UK Myeloma Forum Guideline","volume":"193","author":"Sive","year":"2021","journal-title":"Br J Haematol"},{"key":"B24","volume-title":"Myeloma: diagnosis and management [NICE Guideline NG 35]","year":"2018"},{"key":"B25","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.2044-8309.1995.tb01047.x","article-title":"Delay in seeking a cancer diagnosis: delay stages and psychophysiological comparison processes","volume":"34","author":"Andersen","year":"1995","journal-title":"Br J Soc Psychol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-034244","article-title":"\u201cUnpacking\u201d pathways to lymphoma and myeloma diagnosis: Do experiences align with the Model of Pathways to Treatment? Findings from a UK qualitative study with patients and relatives","volume":"10","author":"Howell","year":"2020","journal-title":"BMJ Open"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btx364","article-title":"UpSetR: an R package for the visualization of intersecting sets and their properties","volume":"33","author":"Conway","year":"2017","journal-title":"Bioinformatics"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp18X698357","article-title":"Early detection of multiple myeloma in primary care using blood tests: a case-control study in primary care","volume":"68","author":"Koshiaris","year":"2018","journal-title":"Br J Gen Pract"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3122\/jabfm.2016.06.150393","article-title":"Presenting signs of multiple myeloma and the effect of diagnostic delay on the prognosis","volume":"29","author":"Goldschmidt","year":"2016","journal-title":"J Am Board Fam Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0127717","article-title":"Age and gender variations in cancer diagnostic intervals in 15 cancers: analysis of data from the UK clinical practice research datalink","volume":"10","author":"Din","year":"2015","journal-title":"PloS One"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05867.x","article-title":"Guidelines on the diagnosis and management of multiple myeloma 2005","volume":"132","author":"Smith","year":"2006","journal-title":"Br J Haematol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70041-4","article-title":"Variation in number of general practitioner consultations before hospital referral for cancer: findings from the 2010 National Cancer Patient Experience Survey in England","volume":"13","author":"Lyratzopoulos","year":"2012","journal-title":"Lancet Oncol"},{"key":"B33","unstructured":"Myeloma, MGUS and related conditions: A Guide for GPs2023"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp15X683545","article-title":"Quantifying the risk of multiple myeloma from symptoms reported in primary care patients: a large case\u2013control study using electronic records","volume":"65","author":"Shephard","year":"2015","journal-title":"Br J Gen Pract"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12790","article-title":"Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis","volume":"97","author":"Ramsenthaler","year":"2016","journal-title":"Eur J Haematol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1282569\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T08:32:52Z","timestamp":1701333172000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1282569\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,30]]},"references-count":35,"alternative-id":["10.3389\/fonc.2023.1282569"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1282569","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,30]]},"article-number":"1282569"}}